U.S. Markets closed

Is There An Opportunity With Teva Pharmaceutical Industries Limited’s (NYSE:TEVA) 43.61% Undervaluation?

Laura Kearns

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize!

Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Teva Pharmaceutical Industries Limited (NYSE:TEVA) as an investment opportunity by taking the expected future cash flows and discounting them to today’s value. I will use the discounted cash flows (DCF) model. Don’t get put off by the jargon, the math behind it is actually quite straightforward. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model. Please also note that this article was written in February 2019 so be sure check out the updated calculation by following the link below.

See our latest analysis for Teva Pharmaceutical Industries

Crunching the numbers

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second ‘steady growth’ period. To begin with we have to get estimates of the next five years of cash flows. For this I used the consensus of the analysts covering the stock, as you can see below. I then discount the sum of these cash flows to arrive at a present value estimate.

5-year cash flow forecast

2019 2020 2021 2022 2023
Levered FCF ($, Millions) $3.30k $3.74k $3.86k $3.99k $4.05k
Source Analyst x3 Analyst x6 Analyst x6 Analyst x5 Analyst x4
Present Value Discounted @ 13.56% $2.91k $2.90k $2.64k $2.40k $2.14k

Present Value of 5-year Cash Flow (PVCF)= US$13b

After calculating the present value of future cash flows in the intial 5-year period we need to calculate the Terminal Value, which accounts for all the future cash flows beyond the first stage. The Gordon Growth formula is used to calculate Terminal Value at an annual growth rate equal to the 10-year government bond rate of 2.7%. We discount this to today’s value at a cost of equity of 13.6%.

Terminal Value (TV) = FCF2023 × (1 + g) ÷ (r – g) = US$4.0b × (1 + 2.7%) ÷ (13.6% – 2.7%) = US$38b

Present Value of Terminal Value (PVTV) = TV / (1 + r)5 = US$38b ÷ ( 1 + 13.6%)5 = US$20b

The total value, or equity value, is then the sum of the present value of the cash flows, which in this case is US$33b. To get the intrinsic value per share, we divide this by the total number of shares outstanding, or the equivalent number if this is a depositary receipt or ADR. This results in an intrinsic value of $30.59. Compared to the current share price of $17.25, the stock is quite undervalued at a 44% discount to what it is available for right now.

NYSE:TEVA Intrinsic value, February 22nd 2019

The assumptions

I’d like to point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don’t agree with my result, have a go at the calculation yourself and play with the assumptions. Because we are looking at Teva Pharmaceutical Industries as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighed average cost of capital, WACC) which accounts for debt. In this calculation I’ve used 13.6%, which is based on a levered beta of 1.49. This is derived from the Bottom-Up Beta method based on comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

Next Steps:

Whilst important, DCF calculation shouldn’t be the only metric you look at when researching a company. What is the reason for the share price to differ from the intrinsic value? For TEVA, I’ve compiled three relevant factors you should further examine:

  1. Financial Health: Does TEVA have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
  2. Future Earnings: How does TEVA’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other High Quality Alternatives: Are there other high quality stocks you could be holding instead of TEVA? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St does a DCF calculation for every US stock every 6 hours, so if you want to find the intrinsic value of any other stock just search here.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.